G1 Therapeutics Inc Q2 2024 Earnings EPS of Beats Estimates, Revenue of 16. ...
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
Slightly above 56% of G1 Therapeutics' investor base is looking to short. The analysis of current outlook of investing in G1 Therapeutics suggests that many traders are alarmed regarding G1 Therapeutics' prospects. G1 Therapeutics' investing sentiment can be driven by a variety of factors including economic data, G1 Therapeutics' earnings reports, geopolitical events, and overall market trends.
GTHX |
Revenue 16.5 million, including 15.8 million from COSELA sales, exceeded estimates of 16.36 million.Net Loss 5.5 million, compared to net income of 8.7
Read at gurufocus.com
 |
G1 Therapeutics Fundamental Analysis
We analyze G1 Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of G1 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of G1 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
G1 Therapeutics is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
G1 Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with G1 Therapeutics stock to make a market-neutral strategy. Peer analysis of G1 Therapeutics could also be used in its relative valuation, which is a method of valuing G1 Therapeutics by comparing valuation metrics with similar companies.
Peers
G1 Therapeutics Related Equities
| FATE | Fate Therapeutics | 18.28 | ||||
| XFOR | X4 Pharmaceuticals | 11.43 | ||||
| SANA | Sana Biotechnology | 9.02 | ||||
| PBYI | Puma Biotechnology | 4.95 | ||||
| HRTX | Heron Therapeuti | 2.59 | ||||
| PDSB | PDS Biotechnology | 1.86 | ||||
| HOOK | Hookipa Pharma | 1.61 | ||||
| DAWN | Day One | 1.53 | ||||
| MREO | Mereo BioPharma | 1.40 | ||||
| BPMC | Blueprint Medicines | 1.35 | ||||
| ANNX | Annexon | 0.94 | ||||
| ABOS | Acumen Pharmaceuticals | 0.44 | ||||
| CRBU | Caribou Biosciences | 0.45 | ||||
| ATRA | Atara Biotherapeutics | 0.65 | ||||
| ALLO | Allogene Therapeutics | 0.80 | ||||
| MGNX | MacroGenics | 1.37 | ||||
| AXSM | Axsome Therapeutics | 1.44 | ||||
| SGMO | Sangamo Therapeutics | 1.74 | ||||
| RCUS | Arcus Biosciences | 2.28 | ||||
| CHRS | Coherus BioSciences | 3.17 | ||||
| AMLX | Amylyx Pharmaceuticals | 3.48 | ||||
| LRMR | Larimar Therapeutics | 4.67 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |